169 related articles for article (PubMed ID: 37965151)
1. Anaerobic growth and drug susceptibility of versatile fungal pathogen
Yadav KK; Nimonkar Y; Green SJ; Dewala S; Dhanorkar MN; Sharma R; Rale VR; Prakash O
iScience; 2023 Nov; 26(11):108304. PubMed ID: 37965151
[TBL] [Abstract][Full Text] [Related]
2. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.
Meletiadis J; Meis JF; Mouton JW; Rodriquez-Tudela JL; Donnelly JP; Verweij PE;
Antimicrob Agents Chemother; 2002 Jan; 46(1):62-8. PubMed ID: 11751112
[TBL] [Abstract][Full Text] [Related]
4. Impact of biofilm formation and azoles' susceptibility in Scedosporium/Lomentospora species using an in vitro model that mimics the cystic fibrosis patients' airway environment.
Mello TP; Lackner M; Branquinha MH; Santos ALS
J Cyst Fibros; 2021 Mar; 20(2):303-309. PubMed ID: 33334714
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the in vitro activity of various antifungal drugs against Scedosporium spp. in aerobic and hyperbaric atmosphere versus normal atmosphere.
Farina C; Marchesi G; Passera M; Diliberto C; Russello G
J Mycol Med; 2012 Jun; 22(2):142-8. PubMed ID: 23518016
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of Pseudallescheria boydii and Scedosporium apiospermum to new antifungal agents.
Zeng J; Kamei K; Zheng Y; Nishimura K
Nihon Ishinkin Gakkai Zasshi; 2004; 45(2):101-4. PubMed ID: 15118667
[TBL] [Abstract][Full Text] [Related]
7. Molecular identification and in vitro antifungal susceptibility of Scedosporium complex isolates from high-human-activity sites in Mexico.
Elizondo-Zertuche M; de J Treviño-Rangel R; Robledo-Leal E; Luna-Rodríguez CE; Martínez-Fierro ML; Rodríguez-Sánchez IP; González GM
Mycologia; 2017; 109(6):874-881. PubMed ID: 29494271
[TBL] [Abstract][Full Text] [Related]
8. [Isolation of Scedosporium apiospermum (teleomorph: Pseudallescheria apiosperma) from an acute myeloid leukemia patient].
Ergin C; Kutlu M; Arıkan Akdağlı S; Sarıbaş Z; Aydeniz Ozansoy F; Sarı I; Dursunoğlu N
Mikrobiyol Bul; 2013 Apr; 47(2):351-5. PubMed ID: 23621736
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
Kirchhoff L; Dittmer S; Buer J; Rath PM; Steinmann J
Int J Antimicrob Agents; 2020 Sep; 56(3):106105. PubMed ID: 32721601
[TBL] [Abstract][Full Text] [Related]
10. Clinical manifestations and susceptibility of Scedosporium/Lomentospora infections at a tertiary medical centre in Taiwan from 2014 to 2021: A retrospective cohort study.
Lao CK; Ou JH; Fan YC; Wu TS; Sun PL
Mycoses; 2023 Oct; 66(10):923-935. PubMed ID: 37449538
[TBL] [Abstract][Full Text] [Related]
11. Activity of voriconazole against corneal isolates of Scedosporium apiospermum.
Shah KB; Wu TG; Wilhelmus KR; Jones DB
Cornea; 2003 Jan; 22(1):33-6. PubMed ID: 12502945
[TBL] [Abstract][Full Text] [Related]
12. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.
Lackner M; de Hoog GS; Verweij PE; Najafzadeh MJ; Curfs-Breuker I; Klaassen CH; Meis JF
Antimicrob Agents Chemother; 2012 May; 56(5):2635-42. PubMed ID: 22290955
[TBL] [Abstract][Full Text] [Related]
13. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.
Castanheira M; Duncanson FP; Diekema DJ; Guarro J; Jones RN; Pfaller MA
Antimicrob Agents Chemother; 2012 Jan; 56(1):352-7. PubMed ID: 22083469
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species.
Trovato L; Scalia G; Palermo CI; Costanzo CM; Oliveri S
Med Mycol; 2019 Jun; 57(4):429-433. PubMed ID: 30124992
[TBL] [Abstract][Full Text] [Related]
15. Antifungal susceptibility patterns for Aspergillus, Scedosporium, and Exophiala isolates recovered from cystic fibrosis patients against amphotericin B, and three triazoles and their impact after long-term therapies.
Brito Devoto T; Hermida-Alva K; Posse G; Finquelievich JL; García-Effrón G; Cuestas ML
Med Mycol; 2023 Aug; 61(8):. PubMed ID: 37591630
[TBL] [Abstract][Full Text] [Related]
16. Characterization of Scedosporium apiospermum glucosylceramides and their involvement in fungal development and macrophage functions.
Rollin-Pinheiro R; Liporagi-Lopes LC; de Meirelles JV; Souza LM; Barreto-Bergter E
PLoS One; 2014; 9(5):e98149. PubMed ID: 24878570
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic susceptibility of human gut-derived facultative anaerobic bacteria is different under aerobic versus anaerobic test conditions.
Kovale L; Nimonkar YS; Green SJ; Shouche YS; Prakash O
Microbes Infect; 2021; 23(9-10):104847. PubMed ID: 34116163
[TBL] [Abstract][Full Text] [Related]
18. Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.
Wu Y; Grossman N; Totten M; Memon W; Fitzgerald A; Ying C; Zhang SX
Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32816726
[No Abstract] [Full Text] [Related]
19. Scedosporium apiospermum infectious scleritis following posterior subtenon triamcinolone acetonide injection: a case report and literature review.
Todokoro D; Hoshino J; Yo A; Makimura K; Hirato J; Akiyama H
BMC Ophthalmol; 2018 Feb; 18(1):40. PubMed ID: 29433463
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of Voriconazole for Invasive Pulmonary Scedosporiosis.
Box H; Negri C; Livermore J; Whalley S; Johnson A; McEntee L; Alastruey-Izquierdo A; Meis JF; Thornton C; Hope W
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439967
[No Abstract] [Full Text] [Related]
[Next] [New Search]
